Alkermes
ALKS
41.45
-0.21
-0.49%
Alkermes
US · ALKS
#1780 by market cap
Listed 1970
41.45
-0.21
-0.49%
Live - 5344 symbols - heartbeat 231s ago
· 2026-10-07 19:54
After-hours
41.45
0.00%
- Market cap
- 6.95B
- P/E (TTM)i
- 109.07
- P/Bi
- 3.84
- EPSi
- 1.43
- Div yieldi
- 0.00%
- 52W posi
- 50%
Reader sentiment
Are you bullish or bearish on ALKS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.2 percentage points.
Institutional ownership
- Held by institutions
- 108.88% -0.25pp
- Institutions
- 509 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund72.64%
Hedge Fund25.37%
VC/PE Fund4.23%
Public Company2.36%
Individual/Insider1.49%
Government Pension Fund1.37%
Sovereign Wealth Fund1.29%
Private Company0.80%
Insurance Company0.65%
Top holders as of 2026-06-30
BlackRock
17.43% · 29.24M sh
Baker Bros. Advisors LP
5.97% · 10.01M sh
Vanguard Portfolio Management, LLC
5.66% · 9.49M sh
State Street Global Advisors
5.46% · 9.16M sh
Vanguard Capital Management, LLC
5.18% · 8.69M sh
T. Rowe Price Group, Inc.
4.67% · 7.83M sh
Renaissance Technologies Corp.
3.85% · 6.46M sh
Geode Capital Management, LLC
2.67% · 4.48M sh
Dimensional Fund Advisors
2.50% · 4.19M sh
Deep Track Capital, LP
2.38% · 4.00M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Richard Pops | Chairperson & CEO | 0.82% |
| Blair Jackson | Chief Operating Officer | 0.14% |
| David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | 0.13% |
| David Daglio | Independent Director | 0.06% |
| Shane Cooke | Director | 0.06% |
| Christian Nichols | Chief Commercial Officer | 0.06% |
| Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | 0.04% |
| Brian McKeon | Independent Director | 0.03% |
| Nancy Snyderman | Independent Director | 0.02% |
| Frank Wilson | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-01 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $41.03 |
| 2026-09-02 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.01 |
| 2026-08-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $46.99 |
| 2026-08-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $24.59–46.99 |
| 2026-08-16 | Christian Nichols | Chief Commercial Officer | Automatic Disposition | -7,576 | $49.19–49.65 |
| 2026-08-04 | Blair Jackson | Chief Operating Officer | Other Derivative Acquisition | +217,534 | $49.61 |
| 2026-08-02 | Nancy Snyderman | Independent Director | Derivative Exercise and Sale | -44,472 | $46.72–50.35 |
| 2026-08-02 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $48.58 |
| 2026-08-02 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–48.58 |
| 2026-08-02 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $48.58 |
| 2026-07-05 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $54.03 |
| 2026-06-30 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $51.46–52.13 |
| 2026-06-30 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–51.46 |
| 2026-06-11 | Christopher I. Wright | Independent Director | Automatic Disposition | -2,000 | $45.10 |
| 2026-06-03 | David Gaffin | Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary | Automatic Disposition | -2,034 | $43.05 |
| 2026-05-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Automatic Disposition | -4,000 | $41.67 |
| 2026-05-31 | Craig Hopkinson | Executive VP of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -5,000 | $19.34–41.67 |
| 2026-05-28 | Samuel Parisi | Interim Principal Accounting Officer & VP of Finance | Derivative Exercise and Sale | -16,217 | $19.34–42.36 |
| 2026-05-20 | Brian McKeon | Independent Director | Derivative Exercise and Sale | -1,475 | $36.95 |
| 2026-05-20 | Brian McKeon | Independent Director | Derivative Exercise and Retained | +4,667 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.